ROIV Stock Price, Chart, Stats & News

Roivant Sciences Ltd.
Save
21.24B
Market cap
–
Current P/E
–
Forward P/E
ROIV chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 91.21% |
Operating margin | -9130.53% |
Pretax margin | -6925.09% |
Net margin | -6079.94% |
Effective tax rate | -9.15% |
ROA | -15.49% |
ROE | -18.32% |
D/E | 0.05x |
Interest coverage ratio | – |
ROIV valuation
P/E | – |
P/S | 1426.02x |
P/B | 4.33x |
P/CF | -24.35x |
P/FCF | -24.75x |
P/OCF | -24.35x |
PEG | 0.21x |
EV multiple | -19.95x |
About
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Similar securities
Based on sector and market capitalization
Report issue











